Mode
Text Size
Log in / Sign up

Cannabis use associated with emotion regulation difficulties in adolescents and young adults

Cannabis use associated with emotion regulation difficulties in adolescents and young adults
Photo by Linoleum Creative Collective / Unsplash
Key Takeaway
Consider cannabis use may link to emotion regulation difficulties in youth, but evidence is limited and causal mechanisms unclear.

This systematic review and meta-analysis examined the association between cannabis use and emotion regulation difficulties in adolescents and young adults aged 12–30 years, with a total sample size of 3,801 participants. The intervention or exposure was cannabis use, compared to non-users or infrequent users, and the primary outcome was self-reported emotion regulation difficulties. The main result indicated that cannabis use was associated with greater emotion regulation difficulties, though specific effect sizes, absolute numbers, p-values, or confidence intervals were not reported in the input.

Safety and tolerability data were not reported in the input. The review was funded by the Health Research Board, and no conflicts of interest were mentioned.

Key limitations include that the results were limited and heterogeneous, with one paper contributing largely to the overall sample size. Only four cross-sectional studies met inclusion criteria, and findings were narratively synthesized due to the limited sample of eligible studies. The evidence remains inconsistent, and results should be observed with caution, as longitudinal studies are needed to clarify causal mechanisms.

In practice, this preliminary evidence suggests a potential link between cannabis use and emotion regulation issues in young populations, but it does not establish causality. Clinicians should recognize the need for more robust, longitudinal, and neurocognitive studies to inform prevention and intervention efforts, avoiding overstatements about global dysregulation or causal mechanisms.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Cannabis is the most widely used illicit drug among young people and is frequently associated with mental health problems. Emotion regulation, the ability to monitor, evaluate, and modulate emotional responses, has been proposed as a mechanism linking cannabis use with psychopathology, but evidence remains inconsistent. This review systematically examined studies investigating the association between cannabis use and self-reported emotion regulation in adolescents and young adults using validated self-report measures. The review was registered with PROSPERO (CRD42024562206) and funded by the Health Research Board. Six electronic databases were searched to June 2025. Eligible studies included participants aged 12–30 years, included a comparison group of non-users or infrequent users, and reported at least one validated measure of emotion regulation (Emotion Regulation Questionnaire, Difficulties in Emotion Regulation Scale, or Cognitive Emotion Regulation Questionnaire). Risk of bias was assessed using the ROBINS-E tool, and findings were narratively synthesised. Only four cross-sectional studies (N = 3,801) met inclusion criteria. Cannabis use was associated with greater emotion regulation difficulties, although results were limited and heterogeneous, with one paper contributing largely to the overall sample size. The most consistent domains implicated were impulse control, goal-directed behaviour, and non-acceptance of emotions, with one study identifying effects limited to females. Preliminary evidence, whilst limited, suggests that cannabis use during adolescence and early adulthood is associated with specific emotion regulation difficulties rather than global dysregulation. However, given the limited sample of eligible studies, results should be observed with caution. Longitudinal and neurocognitive studies are needed to clarify causal mechanisms and inform prevention and intervention efforts. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024562206, PROSPERO CRD42024562206.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.